Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Drug-drug Interaction Study Between Fluconazole and Famitinib in Healthy Subjects
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT05147727
- Locations
- 🇨🇳
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05141422
- Locations
- 🇨🇳
The People's Hospital of Liaoning Province, Shenyang, Liaoning, China
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT05106335
- Locations
- 🇨🇳
Subei People's Hospital of Jiangsu Province, Yangzhou, Jiangsu, China
A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 3
- Registration Number
- NCT05103826
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05095337
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Bioequivalence Study of Hetrombopag in Healthy Subjects
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT05088655
- Locations
- 🇨🇳
The People's Hospital Of Liaoning Province, Shenyang, Liaoning, China
A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05088642
- Locations
- 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
A Trial of Hetrombopag in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05088174
- Locations
- 🇨🇳
West China Second University Hospital Ethics Committee, Chengdu, Sichuan, China
A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05086822
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05088343
- Locations
- 🇨🇳
Xueying General Ding, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath